 | Up a level |
Barbier, Michaela Carla; Fengler, Alicia; Pardo, Esther; Bhadhuri, Arjun; Meier, Niklaus; Gautschi, Oliver (2023). Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland. PharmacoEconomics, 41(12), pp. 1641-1655. Springer 10.1007/s40273-023-01305-3
Mushtaq, Rao; Cortot, Alexis B; Gautschi, Oliver; Mazieres, Julien; Camidge, D Ross (2022). PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer-an IMMUNOTARGET case series. Translational lung cancer research, 11(12), pp. 2412-2417. AME Publishing 10.21037/tlcr-22-329
Panje, Cédric; Lupatsch, J; Barbier, M; Pardo, E; Lorez, M; Dedes, K J; Aebersold, D. M.; Plasswilm, Ludwig; Gautschi, O.; Schwenkglenks, M. (2020). A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland. Annals of oncology, 31(4), pp. 501-506. Oxford University Press 10.1016/j.annonc.2020.01.007
Delaunay, Myriam; Cadranel, Jacques; Lusque, Amélie; Meyer, Nicolas; Gounant, Valérie; Moro-Sibilot, Denis; Michot, Jean-Marie; Raimbourg, Judith; Girard, Nicolas; Guisier, Florian; Planchard, David; Metivier, Anne-Cécile; Tomasini, Pascale; Dansin, Eric; Pérol, Maurice; Campana, Marion; Gautschi, Oliver; Früh, Martin; Fumet, Jean-David; Audigier-Valette, Clarisse; ... (2017). Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. European respiratory journal, 50(2) European Respiratory Society 10.1183/13993003.00050-2017
Rothschild, Sacha; Gautschi, Oliver; Batliner, Jasmin; Gugger, Mathias; Fey, Martin; Tschan, Mario (2017). MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors. Lung cancer, 107, pp. 73-83. Elsevier 10.1016/j.lungcan.2016.06.004
Stutz, Emanuel; Gautschi, Oliver; Fey, Martin F.; Gugger, Mathias; Tschan, Mario; Rothschild, Sacha I. (2014). Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology. Future oncology, 10(2), pp. 211-217. Future Medicine Ltd. 10.2217/fon.13.179
Frauenfelder, T; Puhan, M A; Lazor, R; Von Garnier, Christophe; Bremerich, J; Niemann, T; Christe, Andreas; Montet, X; Gautschi, Oliver; Weder, Bruno J.; Kohler, Martin (2014). Early detection of lung cancer: a statement from an expert panel of the Swiss university hospitals on lung cancer screening. Respiration, 87(3), pp. 254-264. Karger 10.1159/000357049
Burmeister, H; Aebi, S; Studer, C; Fey, M.F.; Gautschi, O (2012). Adherence to ESMO clinial recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Supportive care in cancer, 20(1), pp. 141-7. Berlin: Springer 10.1007/s00520-010-1079-3
Ghadjar, Pirus; Burkhard, Fiona C; Gautschi, Oliver; Thalmann, George N; Studer, Urs E (2011). Induction chemotherapy for unresectable urothelial carcinoma of the bladder. BJU international, 107(6), pp. 894-7. Oxford: Blackwell Science 10.1111/j.1464-410X.2010.09574.x
Ruhstaller, Thomas; Pless, Miklos; Dietrich, Daniel; Kranzbuehler, Helmut; von Moos, Roger; Moosmann, Peter; Montemurro, Michael; Schneider, Paul M; Rauch, Daniel; Gautschi, Oliver; Mingrone, Walter; Widmer, Lucas; Inauen, Roman; Brauchli, Peter; Hess, Viviane (2011). Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). Journal of clinical oncology, 29(6), pp. 626-31. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2010.31.9715
Rothschild, Sacha I; Kappeler, Andreas; Ratschiller, Daniel; Betticher, Daniel C; Tschan, Mario P; Gugger, Mathias; Gautschi, Oliver (2011). The stem cell gene "inhibitor of differentiation 1" (ID1) is frequently expressed in non-small cell lung cancer. Lung cancer, 71(3), pp. 306-11. Amsterdam: Elsevier 10.1016/j.lungcan.2010.06.018
Rothschild, Sacha I; Gautschi, Oliver; Haura, Eric B; Johnson, Faye M (2010). Src inhibitors in lung cancer: current status and future directions. Clinical lung cancer, 11(4), pp. 238-42. New York, N.Y.: Elsevier 10.3816/CLC.2010.n.030
Gautschi, Oliver (2010). The polyamine metabolism: renaissance of an old pathway in oncology. Clinical lung cancer, 11(2), pp. 80-1. New York, N.Y.: Elsevier 10.3816/CLC.2010.n.010
Purnell, Phillip R; Mack, Philip C; Tepper, Clifford G; Evans, Christopher P; Green, Tim P; Gumerlock, Paul H; Lara, Primo N; Gandara, David R; Kung, Hsing-Jien; Gautschi, Oliver (2009). The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. Journal of thoracic oncology, 4(4), pp. 448-54. Hagerstown, Md.: Wolters Kluwer Health/Lippincott Williams & Wilkins 10.1097/JTO.0b013e31819c78fb
Gandara, DR; Kawaguchi, T; Crowley, J; Moon, J; Furuse, K; Kawahara, M; Teramukai, S; Ohe, Y; Kubota, K; Williamson, SK; Gautschi, O; Lenz, HJ; McLeod, HL; Lara, PN Jr; Coltman, CA Jr; Fukuoka, M; Saijo, N; Fukushima, M; Mack, PC (2009). Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. Journal of clinical oncology, 27(21), pp. 3540-3546. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2008.20.8793
Ho, Cheryl; Ochsenbein, Adrian F; Gautschi, Oliver; Davies, Angela M (2008). Early clinical trial experience with vaccine therapies in non-small-cell lung cancer. Clinical lung cancer, 9 Suppl 1, S20-S27. New York, N.Y.: Elsevier 10.3816/CLC.2008.s.004
Gautschi, Oliver; Heighway, Jim; Mack, Philip C; Purnell, Phillip R; Lara, Primo N; Gandara, David R (2008). Aurora kinases as anticancer drug targets. Clinical cancer research, 14(6), pp. 1639-48. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-07-2179
Gautschi, Oliver; Tepper, Clifford G; Purnell, Phillip R; Izumiya, Yoshihiro; Evans, Christopher P; Green, Tim P; Desprez, Pierre Y; Lara, Primo N; Gandara, David R; Mack, Philip C; Kung, Hsing-Jien (2008). Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer research, 68(7), pp. 2250-8. Birmingham, Ala.: American Association for Cancer Research AACR 10.1158/0008-5472.CAN-07-6403
Gautschi, O (2008). Pharmacogenomic Approaches to Individualizing Chemotherapy for Non-.Small Cell Lung Cancer. Clinical lung cancer, 2008;9(S3), pp. 129-38. New York, N.Y.: Elsevier 10.3816/CLC.2008.s.019
Gautschi, Oliver; Ratschiller, Daniel; Gugger, Mathias; Betticher, Daniel C; Heighway, Jim (2007). Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung cancer, 55(1), pp. 1-14. Amsterdam: Elsevier 10.1016/j.lungcan.2006.09.024
Ziegler, Annemarie; Seemayer, Christian A; Hinterberger, Marc; Vogt, Peter; Bigosch, Colette; Gautschi, Oliver; Tornillo, Luigi; Betticher, Daniel C; Moch, Holger; Stahel, Rolf A (2007). Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results. Lung cancer, 57(3), pp. 282-91. Amsterdam: Elsevier 10.1016/j.lungcan.2007.03.025
Gautschi, O; Huegli, B; Ziegler, A; Gugger, M; Heighway, J; Ratschiller, D; Mack, P C; Gumerlock, P H; Kung, H J; Stahel, R A; Gandara, D R; Betticher, D C (2007). Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer letters, 254(2), pp. 265-73. Amsterdam: Elsevier 10.1016/j.canlet.2007.03.008
Gandara, David R; Davies, Angela M; Gautschi, Oliver; Mack, Philip C; Lau, Derick H; Lara, Primo N; Hirsch, Fred R (2007). Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clinical lung cancer, 8 Suppl 2, S61-S67. New York, N.Y.: Elsevier 10.3816/CLC.2007.s.003
Gautschi, Oliver; Zangemeister-Wittke, U.; Stahel, R. A. (2003). Comment on “A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer”, by C. M. Rudin et al. (Ann Oncol 2002; 13: 539–545). Annals of oncology, 14(1), p. 170. Oxford University Press 10.1093/annonc/mdg001
Gautschi, O; Mack, PC; Gandara, DR; Rosell, R. (2010). Pharmacogenomics in Lung Cancer: Predictive Biomarkers for Chemotherapy. In: Pass, HL; Carbone, DP; Johnson, DH; Minna, JD; Turrisi, AT; Scagliotti, GV (eds.) Lung Cancer, Prinicples and Practice. Baltimore USA: Lippincott Williams & Wilkins
Rothschild, S; Gautschi, O (2010). KRAS bei anderen Tumoren. In: Bremen et al.: UNI-MED
Gautschi, Ol; Pless, M (2010). Swiss Trials in Thoracic Oncology. In: Magazine of European Medical Oncology.
Rothschild, S; Betticher, D; Ochsenbein, A; Stahel, R; Bubendorf L.Gugger, M.; Brutsche, M; Pless, M; Gautschi, O (2010). Bedeutung der Histologie für die Therapie des fortgeschrittenen, nicht-kleinzelligen Bronchuskarzinoms. In: Swiss Med Forum
Rothschild, S; Gautschi, O (2010). NSCLC bei Patienten in reduziertem Allgemeinzustand: Mehr oder weniger Chemotherapie? In: Leading Opinions Hämatologie & Onkologie
Rothschild, S; Gautschi, O (2010). Die molekulare Behandlung des Kolonkarzinoms. In: Schweizer Zeitschrift für Onkologie
Ho, C; Davies, AM; Lara, PN; Gautschi, O; Mack, PC; Gumerlock, PH; Gandara, DR (2007). Molecular Targeting in Oncology. In: (pp. 20-40). New York: Humana Press
Gautschi, O (2007). Cellular and molecular biology of lung cancer as the basis for targeted therapy. In: (pp. 30-40). Informa Healthcare
Ho, C; Gautschi, O; Lara, PN; Gandara, DR; Davies, AM (2007). Lung cancer vaccines. In: (pp. 50-60). Informa Healthcare
